IART Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Integra Lifesciences Holdings Corp (IART) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak financial performance, bearish technical indicators, and negative sentiment from analysts. While there are no significant positive catalysts or trading signals, the stock may be worth monitoring for future improvements in financials or sentiment.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 48.225, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 8.807 and 8.522, while resistance levels are at 9.731 and 10.016. Overall, the technical indicators suggest a bearish trend.
No significant positive catalysts identified. The MACD histogram is slightly positive, which could indicate mild bullish momentum.
Weak financial performance in Q4 2025 with declining revenue (-1.74% YoY), net income (-108.77% YoY), and EPS (-108.00% YoY). Analysts have lowered price targets and maintain negative or neutral ratings. No recent news or significant insider/hedge fund activity to drive momentum.
In Q4 2025, revenue dropped to $434.93M (-1.74% YoY), net income fell to -$1.70M (-108.77% YoY), and EPS decreased to -$0.02 (-108.00% YoY). Gross margin also declined to 57.02% (-3.71% YoY), indicating worsening profitability.
Analysts have a negative to neutral stance on IART. Citi maintains a Sell rating with a price target of $9, JPMorgan has an Underweight rating with a price target of $11, and Wells Fargo has an Equal Weight rating with a price target of $12. Recent price target adjustments reflect cautious sentiment and a lack of confidence in near-term growth.
